NTRK3

NT-3 growth factor receptor

80,467 patent compounds predicted against NTRK3, 55,581 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL98881	0.57	3/20
SCHEMBL100391	0.50	3/20
SCHEMBL100329	0.49	3/20
SCHEMBL100040	0.48	3/20
SCHEMBL100903	0.47	3/20
Trifluoroacetic Acid (SCHEMBL101057)	0.45	3/20
Crizotinib (SCHEMBL93829)	1.00	2/20
Crizotinib (SCHEMBL94020)	1.00	2/20
Ruxolitinib (SCHEMBL99225)	1.00	2/20
Ruxolitinib (SCHEMBL101279)	1.00	2/20
SCHEMBL99245	0.98	2/20
SCHEMBL99371	0.98	2/20
SCHEMBL98692	0.92	2/20
Ruxolitinib (SCHEMBL99771)	0.84	2/20
Ruxolitinib (SCHEMBL100078)	0.84	2/20
SCHEMBL101345	0.82	2/20
SCHEMBL100845	0.80	2/20
SCHEMBL98773	0.77	2/20
SCHEMBL100309	0.77	2/20
SCHEMBL100546	0.73	2/20

Germline variants in NTRK3 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full NTRK3 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to NTRK3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors	PHASE2	RECRUITING
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors	PHASE2	COMPLETED
A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer	PHASE2	WITHDRAWN
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	PHASE2	ACTIVE_NOT_RECRUITING
A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities	PHASE1/PHASE2	RECRUITING
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients	PHASE2	RECRUITING
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer	PHASE1/PHASE2	COMPLETED
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations	PHASE1/PHASE2	RECRUITING
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors	PHASE2	RECRUITING
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy	PHASE2	COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	PHASE1	COMPLETED
A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations	PHASE1	UNKNOWN
AZD7451 for Recurrent Gliomas	PHASE1	COMPLETED
Study of FCN-098 in Patients With Advanced Solid Tumor	PHASE1	UNKNOWN
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib	nan	COMPLETED
Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion	nan	COMPLETED
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma	nan	COMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.	nan	ACTIVE_NOT_RECRUITING
Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion	nan	APPROVED_FOR_MARKETING
Regular Exercise Improves Physical Capacity and Promotes Neurotrophins in Patients With Multiple Sclerosis	nan	COMPLETED
Studying Gene Expression in Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain (SPAINTRK)	nan	COMPLETED
Association of Urine BDNF and NGF With Lower Urinary System Parameters	nan	RECRUITING
Spanish Study for Molecular Characterization of Thyroid Carcinoma	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a NTRK3 binder may also engage these)

Protein	Name	Similarity
P24786	—	1.000	P24786 →
Q91044	—	1.000	Q91044 →
Q5IS37	—	1.000	Q5IS37 →
Q5IFJ9	—	1.000	Q5IFJ9 →
Q6VNS1	—	1.000	Q6VNS1 →
Q03351	—	1.000	Q03351 →
Q5IS82	—	1.000	Q5IS82 →
Q91987	—	1.000	Q91987 →
NTRK2	BDNF/NT-3 growth factors receptor	1.000	landscape →
P15209	—	0.996	P15209 →
Q63604	—	0.995	Q63604 →
Q01887	—	0.983	Q01887 →
ROR1	Inactive tyrosine-protein kinase transmembrane receptor ROR1	0.978	landscape →
P34925	—	0.975	P34925 →
Q9Z139	—	0.972	Q9Z139 →
P11273	—	0.968	P11273 →
Q8TDF5	—	0.965	Q8TDF5 →
Q8R4I7	—	0.965	Q8R4I7 →
E9PZ19	—	0.964	E9PZ19 →
PRKD1	Serine/threonine-protein kinase D1	0.963	landscape →
TGFBR2	TGF-beta receptor type-2	0.963	landscape →
Q7TQP6	—	0.962	Q7TQP6 →
Q5GIG6	—	0.961	Q5GIG6 →
TNNI3K	Serine/threonine-protein kinase TNNI3K	0.961	landscape →
P00535	—	0.961	P00535 →
Q91009	—	0.960	Q91009 →
D3ZB51	—	0.960	D3ZB51 →
Q90999	—	0.960	Q90999 →
Q5XIS9	—	0.959	Q5XIS9 →
P38438	—	0.959	P38438 →